

HHS Public Access

Author manuscript Genet Med. Author manuscript; available in PMC 2017 January 01.

Published in final edited form as: Genet Med. 2016 January ; 18(1): 41–48. doi:10.1038/gim.2015.25.

High Incidence of Unrecognized Visceral/Neurological Lateonset Niemann-Pick Disease, type C1 Predicted by Analysis of Massively Parallel Sequencing Data Sets

Christopher A. Wassif^{1,2,*}, Joanna L. Cross^{1,2,*}, James Iben¹, Luis Sanchez-Pulido³, Antony Cougnoux¹, Frances M. Platt², Daniel S. Ory⁴, Chris P. Ponting³, Joan E. Bailey-Wilson⁵, Leslie G. Biesecker⁶, and Forbes D. Porter¹

¹Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, US

²Department of Pharmacology, University of Oxford, Oxford OX1 3QT, United Kingdom

³MRC Functional Genomics Unit, Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3PT, UK

⁴Diabetic Cardiovascular Disease Center, Washington University School of Medicine, St. Louis, MO, USA

⁵Statistical Genetics Section, Computational and Statistical Genomics Branch, Department of Health and Human Services, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA

⁶Clinical Genomics Section, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA

Abstract

Purpose—Niemann-Pick disease, type C (NPC) is a recessive, neurodegenerative, lysosomal storage disease caused by mutations in either *NPC1* or *NPC2*. The diagnosis is difficult and frequently delayed. Ascertainment is likely incomplete due to both these factors and that the full phenotypic spectrum may not have been fully delineated. Given the recent development of a blood-based diagnostic test and development of potential therapies, it is important to understand the incidence of NPC and to define at risk patient populations.

Method—We evaluated data from four large massively parallel exome sequencing data sets. Variant sequences were identified and classified as pathogenic or non-pathogenic based on a combination of literature review and bioinformatic analysis. This methodology provided an unbiased approach to determining the allele frequency.

Corresponding Author: Christopher A. Wassif M.S., Senior Technical Specialist/Research Associate, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Candidate for the degree of Doctorate in Philosophy, University of Oxford, 9000 Rockville Pike Building CRC Room 1E-3288, Bethesda, MD 20892-1830, (301) 496-6664, (301) 480-5791 (fax).

^{*}Authors contributed equally to this work

All other authors report no conflict of interest.

Results—Our data suggests an incidence rate for NPC1 and NPC2 of 1/92,104 and 1/2,858,998, respectively. However, evaluation of common *NPC1* variants, suggests that there may be a late-onset NPC1phenotype with a markedly higher incidence on the order of 1/20,000–39,000.

Conclusions—We determined a combined incidence of classical NPC of 1/89,229 or 1.12 affected patients per 100,000 conceptions, but predict incomplete ascertainment of a lateonset phenotype of NPC1. This finding strongly supports the need for increased screening of potential patients.

Keywords

Next Generation sequence study; Niemann-Pick disease; type C; NPC; Allele frequency

Introduction

Niemann-Pick Type C (NPC) is an autosomal recessive, neurodegenerative lethal disorder with a clinical incidence of $1:104,000^{1-3}$. This was considered to be a minimal estimate due to incomplete ascertainment of atypical phenotypes or limitations of current diagnostic testing. NPC is caused by disruption of either NPC1 or NPC2 with mutations of NPC1 accounting for 95% of patients^{1; 2}. Loss of function of either NPC1 or NPC2 results in the accumulation of unesterified cholesterol and glycosphingolipids within the late-endosome/ lysosome of all cells. Although the clinical presentation and progression of NPC is a continuous spectrum, patients can be classified into four general categories based on age of neurological onset. These categories are early-infantile, late-infantile, juvenile and adolescent/adult-onset¹. In the early infantile, late-infantile, and juvenile forms of the disease patients may initially present with neonatal cholestasis or hepatosplenomegaly. A small subset of NPC patients die of systemic liver disease usually during the neonatal period¹. However in the majority of NPC patients the liver disease frequently resolves, but neurological signs and symptoms follow^{1; 2}. Neurological symptoms are insidious and heterogeneous in nature, often initially manifesting in a non-specific manner (e.g., clumsiness or difficulty with school work) but commonly progress to include variable degrees of cerebellar ataxia, vertical supranuclear gaze palsy, gelastic cataplexy, seizures, and dementia. These neurological manifestations are invariably progressive^{4; 5} and ultimately result in death.

The current diagnosis of NPC is based upon filipin staining of unesterified cholesterol in cultured fibroblasts or molecular testing. Filipin staining requires a skin biopsy, is performed in only a few specialized diagnostic laboratories worldwide and is not always conclusive. Molecular testing of *NPC1* and *NPC2* is also available; however, molecular testing in practice also has weaknesses. It is currently still inconclusive in 12–15% of the cases, because of unknown pathogenicity of the changes, lack of study of allele segregation, existence of one (possibly 2) unidentified mutant allele. Combined with the frequently nonspecific and insidious nature of the neurological disease onset, the difficulty of diagnosis contributes to a diagnostic delay on the order of 4–5 years² for the late infantile and juvenile forms of the disease. The diagnostic delay in the adolescent/adult-onset is likely greater but the full extent of that delay cannot be determined due to a limited number of reported cases. Recently a sensitive blood-based diagnostic test, which detects elevated oxysterols, has been

developed and this blood-based test could economically and rapidly be used to screen potential patients⁶.

A number of therapies for NPC are actively being developed. Miglustat, a glycosphingolipid synthesis inhibitor, although not approved in the United States for treatment of NPC1, has been approved in the European Union and other countries for the treatment of NPC. 2-hydroxypropyl- β -cyclodextrin (HP- β -CD) has shown significant promise in both mouse and feline (Charles Vite personal communication) models of NPC1 and is currently in a phase 1/2 trial (NCT01747135) at the NIH. The development of HP- β -CD for NPC1 has been reviewed by Ottinger *et al.*⁷ Other potential therapies under development include HDAC inhibitors^{8–10}, HSP70 (F. Platt), and delta-tocopherol¹¹. Given the rapid development of potential therapeutic interventions, it is critical that the incidence of NPC and its full clinical spectrum be fully defined.

An increasing number of adult-onset NPC patients are being reported^{1; 12–14}. Psychiatric symptoms can be prominent^{12–15} although affected adults without neurological manifestations have also been reported^{16–18}. The full phenotypic spectrum of adult-onset NPC disease has yet to be delineated. This led us to question whether the incidence of NPC might be greater than previous clinical estimates due to incomplete ascertainment. To estimate the incidence of NPC in a manner that is independent of clinical recognition of cases, we sought to determine a pathogenic carrier frequency of *NPC1* and *NPC2* variants utilizing data from four independent massively parallel exome sequencing projects, or next generation sequencing projects. Our data indicates that the classical incidence of NPC likely occurs at the clinically predicted rate of approximately 1:90,000, and suggest that there may be a late-onset phenotype or variant form with an incidence potentially as high as 1:19,000–36,000.

Material and Methods

We have recently reported the determination of the pathogenic allele frequency of the 7-dehydrocholesterol reductase gene (DHCR7)¹⁹. We utilized a similar approach for the determination of the variant frequency in NPC.

Data Sets

Four large independent massively parallel exome sequencing projects, or next generation sequencing projects were utilized. These data sets are the NHLBI GO Exome Sequencing Project (ESP)²⁰, V3 release of the 1000 Genomes Project²¹, ClinSeq^{®22}, and a database from a NIH inter-institute collaboration on Autism (PIs: FD Porter, J Bailey-Wilson, E Tierney, A. Thurm). ESP contributed a maximum number of 13,006 chromosomes, 1000 Genome Project contributed 2,184 chromosomes, ClinSeq[®] contributed 1,902 chromosomes and the NIH inter-institute collaboration on Autism project contributed 662 chromosomes. Thus, a maximum total of 17,754 chromosomes were analyzed and this number was utilized as the denominator in total frequency calculations. None of these datasets included patients evaluated for NPC nor did we identify any individuals with two pathogenic mutations, so we considered them to be unbiased with respect to variation in *NPC1* and *NPC2*.

Determination of Variant Calls and Annotation

Variant calls were downloaded for regions overlapping *NPC1* and *NPC2*, by Perl script for every base of the coding exons plus/minus 5 base pairs of exon sequence when available. Mutations were annotated using SNPnexus²³ using Refseq annotations²⁴, pathogenicity predictions were performed using Polyphen-2,²⁵ SIFT,²⁶ Mutation assessor²⁷. Intronic variations detected within 5 bases of intron exon boundaries were analyzed by MaxEntScan²⁸. Untranslated regions variations were excluded from the analysis of these data sets.

Determination of Pathogenicity of the Variant Call

Determination of the pathogenicity of a variant allele was a multistep process that utilized both bioinformatic tools and manual curation. We began by comparing the variants found in the data sets against the professional version of the Human Gene Mutation Database (HGMD[®])²⁹ and the existing database of 78 patients with NPC1 in the NIH Cohort (PI: FD Porter) to determine which variants had been previously identified in patients known to have NPC. Since inclusion in HGMD does not require identification in a patient, primary literature was reviewed to determine the nature and manner in which the variations were detected. Variants were mapped onto known protein tertiary structures as part of the bioinformatic approach, identifying variable to conserved residues and possible interactions (Figures 1 and 2). Modeling of the variant NPC2 protein was performed using I-TASSER³⁰.

Single coding nucleotide variants were interrogated in silico by three different predictive software packages Polyphen-2,²⁵ SIFT,²⁶ Mutation assessor²⁷. Polyphen-2 provides a predicted assignment of "Benign", "Possibly Damaging", or "Probably Damaging" as well as a false discovery rate (FDR) for each single coding nucleotide variant call. For the determination of the pathogenesis of a single coding nucleotide variants Polyphen-2 calls of "Possibly Damaging", or "Probably Damaging" were considered pathogenic. SIFT uses the same terminology as Polyphen-2 and the same approach was used. Mutation assessor has four predictive determinants predictive nonfunctional low, non-functional neutral, functional (medium), and functional (high). Mutation assessor predictions of functional (medium), and functional (high) where considered pathogenic. When the three predictive algorithms were discrepant and no published data supporting pathogenicity was available, we accepted the prediction of two of the three programs. Potential splice variants were processed in MaxEntScan²⁸ to provide a predictive determination of the variants affect on splicing; these were reported as "Strongly Negative", "Negative", or "Neutral". Potential splice variants that were classified as Negative or Strongly Negative were considered to be pathogenic. All pathogenic variants were assumed to be fully penetrant.

Determination of predicted disease incidence

Once potential pathogenic variants were identified and a carrier frequency determined, the predicted disease incidence was calculated assuming a Hardy-Weinberg-Equilibrium (HWE). For this estimate we assumed that all pathogenic variants were fully penetrant. The HWE model also assumes that allelic variation is at equilibrium and thus not undergoing active selective pressure. Given that NPC1 is a receptor for filoviruses and its association with body mass, an assumption of neutral selection may not be correct. However, Al-Daghri

*et al*³¹ concluded selective pressure on NPC1 in humans is weak to neutral. We made the assumption that allelic frequencies were consistent across different ethnic groups represented in our dataset. The potential error making this assumption is greatest for the ESP cohort given that it includes large number of individuals of either European or African descent. We evaluated our data for reduction of heterozygosity due to ethnic difference (Wahlund effect) by determining a weighted frequency; however, only negligible changes were observed for any of the NPC1 or NPC2 pathogenic alleles (data not shown). Given the negligible effect the weighted frequencies were not applied to carrier frequency calculations.

Cloning and Sequence Analysis of the c.441+1G>A Variant Discovered in NPC2

Two heterozygous Epstein-Barr virus transformed lymphoblast cell lines for the c. 441+1G>A variant, NIMH 42 and NIMH 77, were identified in the NIH inter-institute collaboration on Autism. These 2 lines and one control line were grown under standard growth conditions15% fetal bovine serum in RPMI (Life Technologies) for 3 days. Cell pellets were isolated and mRNA isolated as per manufactures protocol (Qiagen). Forward primer NPC2-F3 5'-GGTGGAGTGGCAACTTCAGG-3' and Reverse primer NPC2-R2 5'-CACTGGATACCATTGGAGAGC-3' were used to reverse transcribe the mRNA using Superscript III One-step RT-PCR System (Life Technologies). The cDNA was visualized on a 1.5% agarose gel. One band was observed for WT and two for NIMH 42 and NIMH 77. All bands were gel purified and cloned into the TOPO TA Cloning Kit for Sequencing (Life Technologies). Isolated colonies were grown overnight in LB-ampicillin and plasmid DNA was isolated (Qiagen). Sequencing was performed on a 3500xL Genetic Analyzer (Life Technologies) using BigDye sequencing kit as per manufacturer's protocol.

Results

Analysis of exomic sequence data from 17,754 chromosomes as compared to the human reference sequence for *NPC1* and *NPC2*, led to the identification of 16,455 and 271 nonsynonymous sequence variants in *NPC1* and *NPC2*, respectively. The 16,455 variants identified in NPC1 were comprised of 147 distinct variants that included 129 coding single nucleotide base variants, 9 splice site changes, and 9 insertions/deletions (Table 1). The 271 nonsynonymous variants identified in *NPC2* included 14 distinct changes consisting of 12 coding single nucleotide base variants and 2 splice site changes (Table 2).

The Human Gene Mutation Database HGMD^{®29} was queried to establishing what observed variants in this data set might be pathogenic. For *NPC1* (Table 1) and *NPC2* (Table 2), 33 (32 pathogenic and one benign variant) of 147 (22.4%) and 5 out of 14 (35.7%) variants, respectively, had previously been reported in HGMD[®]. One additional novel *NPC1* variant, c.2524T>C (p.F842L), was present in the NIH cohort (Table 1). The combination of Polyphen-2, SIFT, and Mutation assessor classified 53 *NPC1* and 8 *NPC2* coding nucleotide variants as pathogenic by our criteria. Of the predicted pathogenic variants 27 (51%) and 6 (75%) have not been reported in HGMD[®] for *NPC1* and *NPC2* respectively. Polyphen-2 also calculates a false discovery rate (FDR). For *NPC1* and *NPC2* predicted variants, the average FDR for a prediction of "Probably" or "Possibly" damaging were 0.04% and 0.03% respectively. These low mean FDRs had a negligible effect on the carrier incidence estimate and thus were not applied to either *NPC1* or *NPC2* carrier frequency calculations.

For *NPC1* and *NPC2*, 2 out of 9 and 1 of 2, potential splice mutations were predicted to be pathogenic. Of the nine insertion/deletions (indels) identified in *NPC1*, a two base pair deletion, c.2020_2021del, was observed 319 times only in the ESP data set and thus was removed as a technical artifact unique to the ESP data set. The eight other *NPC1* indels result in a frameshift, and thus were considered pathogenic. No indels were identified in *NPC2*.

Based on the above analysis, for NPC1 we initially considered the 68 distinct variants meeting the criteria of pathogenic (54 identified by predictive software to be pathogenic, 4 indicated by the predictive software as "benign" but known to be pathogenic, the 2 splice variants, and the 8 insertion/deletions). This accounted for 371 pathogenic alleles with an estimated carrier rate of 2.09% (371/17,754) and a predicted NPC incidence of 1/9,160. Given the order of magnitude difference between this number and clinical estimates, this prediction is likely a significant overestimation. Thus we applied manual curation to the *NPC1* data set. Four variants, c.665A>G (p.N222S), c.1532C>T (p.T511M), c.2882A>G (p.N961S), and c.3598A>G (p.S1200G), accounted for 254 out of the 371 (68%) predicted pathogenic alleles. Allelic frequencies for these four alleles were 0.400, 0.287, 0.389 and 0.355 percent respectively. Given that their individual allelic frequencies exceed the allelic frequency of p.I1061T (0.028%), the most commonly reported mutant allele in patients with mutations in NPC1, by more than a factor of 10 (Table 1), it is not plausible that these alleles are associated with classical NPC disease. Excluding these four high frequency variants based on this assertion left 117 pathogenic alleles or a 0.659% (117/17,754) carrier rate. This carrier rate predicts an incidence of NPC attributable to NPC1 of 1/92,104.

We further evaluated the decision to exclude the four high frequency alleles based on lack of an association with classical NPC disease. Although, all three predictive packages indicate both p.N222S and p.N961S to be non-pathogenic these two variants have been reported in "visceral-only" or adult-onset NPC1 cases. The p.N222S variant was reported in combination with a p.I1061T mutation in a single adult onset (35 yr) patient with variant filipin staining³². This patient initially presented with visceral disease (hepatosplenomegaly) and later manifested ataxia at 44 years of age. We have identified a p.N222S variant in combination with c.1402T>G, (p.C468G) in teenage sisters diagnosed based on splenomegaly. The second allele in this sib pair, p.C468G is predicted by Polyphen-2 to be "Probably" damaging. Pathological analysis of the spleen in the older sibling was suggestive of Niemann-Pick disease, but filipin staining was inconclusive. Neurological symptoms were absent and signs were very minor with deep tendon hyperreflexia and minor auditory brainstem response abnormalities noted on evaluation at 15 and 13 years of age respectively. NIH severity score for both was 1⁴. Plasma oxysterol concentrations were consistent with a diagnosis of NPC in these two subjects. Mapping of p.N222S to the known tertiary structure provided no additional evidence for the pathogenicity of this residue (Figure 2). The p.N961S (c.2882A>C) variant has been reported in a compound heterozygous state with p.S666N, (c.1997G>A) (with a Polyphen-2 prediction of "Probably" damaging) in an adult case with subclinical hepatosplenamegaly and lymphadenopathy noted on autopsy following death due to acute pulmonary embolism and myocardial infarction¹⁶. Although no neurological symptoms were reported, brain pathology was notable for distended neurons

with increased lipofuscin granules. Assuming one or both of these variants are pathogenic, fully penetrant and associated with late onset NPC disease, the total disease incidence of NPC1 would range from 1/19,077–1/36,420.

Although predicted to be probably damaging by Polyphen-2, neither p.T511M nor p.S1200G have been reported in NPC1 patients. Millat et al³³ reported p.T511M as a novel nonpathological coding single nucleotide variant. The p.S1200G variant was reported in an "NPC uncertain" case in the recent ZOOM study¹⁴. This subject, patient 5 in the ZOOM study, was a compound heterozygote for p.V664M, a known *NPC1* mutation, but plasma cholestane-3 β ,5 α ,6 β -triol testing⁶ was negative. Current data do not support classification of either p.T511M or p.S1200G variants as pathogenic alleles.

Sequence analysis of NPC2 (Table 2) identified 151 potential pathogenic alleles and calculated a pathogenic carrier frequency of 0.85% (151/17,754). Again the predicted disease incidence, 1/55,297 did not appear to be realistic unless one proposed an extreme degree of under-ascertainment. Thus, we similarly applied manual curation to the NPC2 data set. Review of the NPC2 data identified two high frequency variants that dominated the frequency calculation c.441+1G>A and c.88G>A (p.V30M), both variants are reported in HMGD[®]. The splice variant, c.441+1G>C, was predicted to be "Strongly Negative" by MaxEntScan. Molecular analysis of independent cell lines revealed multiple splicing events. The most prominent errant splicing event results in the insertion of 16 bases that leads to the alteration of the terminal 4 amino acids and the addition of 86 additional amino acids to the protein (supplemental figure1). Multiple lines of evidence strongly indicate that this errant splicing results in a functional protein. First, the variant has not been reported in association with a patient with NPC. Second, modeling of the variant protein using I-TASSER³⁰ found no alterations to the cholesterol binding pocket or stability of the protein (data not shown). Finally, Huang et al. have demonstrated that generation of an NPC2 fusion protein with mCherry fused to the carboxy-terminal end of the protein is fully functional and is able to correct the NPC cellular phenotype in $Npc2^{-/-}$ mouse embryonic fibroblasts³⁴. As such we have excluded c.441+1G>C as a pathogenic allele. The p.V30M variant, with a allelic frequency of 0.197%, is predicted to be possibly damaging by Polyphen-2 and SIFT but considered non-pathogenic by mutation assessor. The one reported NPC subject with the p.V30M variant was classified as a phenotypic NPC variant, a second mutation was not identified and near normal levels of cholesterol esterification was reported in skin fibroblasts³⁵. Inclusion of the p.V30M allele predicts a disease incidence of NPC attributable to NPC2 of 1/402,400 and that NPC2 should account for 18.6% of patients with NPC. This latter prediction conflicts with clinical data indicating that NPC2 account for only 2-5% of all patients with NPC1; 2. Sequence alignment and structural analyses demonstrate that the p.V30 residue is not evolutionarily conserved and is present in a structurally variable region of the NPC2 protein well away from its binding pocket (Figure 1). Furthermore, p.V30M is found at a higher frequency than any known pathogenic NPC2 allele, coupled with the lack of evidence supporting functional importance and ultimately the lack of any clinical correlation, has lead us to exclude p.V30M as a pathogenic allele. We are, therefore, left with 21 pathogenic alleles (0.118% carrier frequency) and a predicted disease incidence of 1/2,858,998 conceptions for NPC2.

Based on the above analysis of both *NPC1* and *NPC2*, the combined incidence is predicted to be 1/89,229 or 1.12 cases per 100,000 conceptions and the fraction of NPC2 cases is predicted to be 3.1%. The predicted number of cases is slightly more than the 0.96 cases per 100,000 conceptions reported by Vanier² when she accounted for prenatal cases and the fraction of NPC2 cases is consistent with prior clinical observation of $2-5\%^{1-3}$.

Discussion

The impact of NPC1 variation on human health may be significant. Work by multiple groups has demonstrated that c.644A>G (p.H215R) is associated with obesity³⁶. In this analysis of *NPC1* variants we identified the p.H215R variant in almost a third of the *NPC1* alleles. Our work now demonstrates that two relatively common *NPC1* variants with a combined carrier frequency approaching 0.8% may contribute, in compound heterozygous state, to a late-onset NPC1 phenotype for which the phenotypic spectrum and clinical significance remains to be defined. This late-onset NPC1 phenotype may represent a milder manifestation of NPC1 deficiency with predominately visceral manifestations. The degree to which this late-onset NPC1 phenotype is associated with high frequency NPC1 alleles and the adult-onset NPC1 phenotype that includes significant neurological and psychological symptoms also remains to be defined.

Failure to ascertain certain alleles in patients such as the p.V30M in *NPC2* or the p.T511M and p.S1200G in *NPC1* could be due to prenatal lethality; however, as NPC is an autosomal recessive disorder, it is difficult to hypothesize a plausible mechanism, such as a dominant inhibitory function, by which these alleles would uniquely result in prenatal lethality.

Based on clinical case reports, one needs to consider the possibility that p.N222S and p.N961S maybe pathogenic with allelic frequencies of 0.400 and 0.389 percent respectively. The evidence for clinical relevance is strongest for p.N222S, which has been observed in two independent cases with similar visceral and delayed neurological manifestations, variant filipin staining in fibroblasts, and positive plasma oxysterol testing in the siblings. Assuming pathogenicity is related to a compound heterozygous state and full penetrance, the combined frequency of p.N222S with another pathogenic *NPC1* mutation would be 1/35,667. Although only limited data are available, if one includes p.N961S based on a single report with no supporting diagnostic testing, the incidence of a late onset variant of NPC1 disease would increase to 1/19,077. Another possible to explanation of these high predicted incidences is that some individuals harboring these variants either in combination with another pathogenic allele or in the homozygous state may be asymptomatic or only manifest subclinical signs.

Leveraging existing "whole exome sequence" data we have estimated the disease incidence of NPC utilizing both bioinformatic tools and manual curation. With respect to classical NPC disease, we estimate that the incidence of NPC1 and NPC2 are on the order of 1/92,000 and 1/2,900,000, respectively, with a combined incidence of approximately 1/89,000. These estimates are in agreement with previous clinical estimates. Thus, our data does not support significant under-ascertainment of classical NPC cases. Concurrence with clinical data also suggests that we are not missing a significant number of alleles, such as

large indels or intronic mutations that are not detected by "whole exome sequencing." However, our data suggests that there may be significant under-ascertainment of a late-onset NPC1 phenotype. This late-onset phenotype may present as visceral-only or neurological mild NPC1, and with a potential incidence of 1/19,000–1/39,000. Further work is necessary to fully delineate this late-onset NPC1 phenotype, but the current study suggests that NPC should be considered in individuals with visceral lipidosis or unexplained neurological and psychiatric symptoms.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

J. L. C., J. I., C.L., A. T., S. S., J.E.B-W., L. G. B., F. D. P., and C. A. W. supported by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development or the National Human Genome Research Institute intramural research programs, DHHS. J.L.C. C.A.W. is a NIH/Oxford Scholar and J.L.C is a Wellcome Trust/NIH Scholar. F.M.P. is a Royal Society Wolfson Research Merit Award holder. L. G. B. is an uncompensated advisor to the Illumina Corporation and receives royalties from the Genentech Corporation; all other authors report no conflict of interest.

L. G. B. is an uncompensated advisor to the Illumina Corporation and receives royalties from the Genentech Corporation;

References

- Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F. Group, N.-C.G.W. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Molecular genetics and metabolism. 2012; 106:330–344. [PubMed: 22572546]
- Vanier MT. Niemann-Pick disease type C. Orphanet journal of rare diseases. 2010; 5:16. [PubMed: 20525256]
- 3. Jahnova H, Dvorakova L, Vlaskova H, Hulkova H, Poupetova H, Hrebicek M, Jesina P. Observational, retrospective study of a large cohort of patients with Niemann-Pick disease type C in the Czech Republic: a surprisingly stable diagnostic rate spanning almost 40 years. Orphanet journal of rare diseases. 2014; 9:140. [PubMed: 25236789]
- 4. Yanjanin NM, Velez JI, Gropman A, King K, Bianconi SE, Conley SK, Brewer CC, Solomon B, Pavan WJ, Arcos-Burgos M, et al. Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B:132–140. [PubMed: 19415691]
- te Vruchte D, Speak AO, Wallom KL, Al Eisa N, Smith DA, Hendriksz CJ, Simmons L, Lachmann RH, Cousins A, Hartung R, et al. Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. Journal of Clinical Investigation. 2014; 124:1320–1328. [PubMed: 24487591]
- Porter FD, Scherrer DE, Lanier MH, Langmade SJ, Molugu V, Gale SE, Olzeski D, Sidhu R, Dietzen DJ, Fu R, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Science translational medicine. 2010; 2:56ra81.
- Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, Janssen M, Brewster M, Scott I, Xu X, Cradock J, et al. Collaborative development of 2-hydroxypropyl-beta-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Current topics in medicinal chemistry. 2014; 14:330–339. [PubMed: 24283970]
- Kim SJ, Lee BH, Lee YS, Kang KS. Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor. Biochem Biophys Res Commun. 2007; 360:593–599. [PubMed: 17624314]

- Munkacsi AB, Chen FW, Brinkman MA, Higaki K, Gutierrez GD, Chaudhari J, Layer JV, Tong A, Bard M, Boone C, et al. An "exacerbate-reverse" strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease. J Biol Chem. 2011; 286:23842–23851. [PubMed: 21489983]
- Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, Farley N, Helquist P, Wiest O, Maxfield FR. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:5620–5625. [PubMed: 21436030]
- Xu M, Liu K, Swaroop M, Porter FD, Sidhu R, Firnkes S, Ory DS, Marugan JJ, Xiao J, Southall N, et al. delta-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. J Biol Chem. 2012; 287:39349–39360. [PubMed: 23035117]
- Zech M, Nubling G, Castrop F, Jochim A, Schulte EC, Mollenhauer B, Lichtner P, Peters A, Gieger C, Marquardt T, et al. Niemann-Pick C disease gene mutations and age-related neurodegenerative disorders. PloS one. 2013; 8:e82879. [PubMed: 24386122]
- Schicks J, Muller Vom Hagen J, Bauer P, Beck-Wodl S, Biskup S, Krageloh-Mann I, Schols L, Synofzik M. Niemann-Pick type C is frequent in adult ataxia with cognitive decline and vertical gaze palsy. Neurology. 2013; 80:1169–1170. [PubMed: 23427322]
- 14. Bauer P, Balding DJ, Klunemann HH, Linden DE, Ory DS, Pineda M, Priller J, Sedel F, Muller A, Chadha-Boreham H, et al. Genetic screening for Niemann-Pick disease type C in adults with neurological and psychiatric symptoms: findings from the ZOOM study. Human molecular genetics. 2013; 22:4349–4356. [PubMed: 23773996]
- Bonnot O, Klunemann HH, Sedel F, Tordjman S, Cohen D, Walterfang M. Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review. Orphanet journal of rare diseases. 2014; 9:65. [PubMed: 24775716]
- 16. Dvorakova L, Sikora J, Hrebicek M, Hulkova H, Bouckova M, Stolnaja L, Elleder M. Subclinical course of adult visceral Niemann-Pick type C1 disease. A rare or underdiagnosed disorder? Journal of inherited metabolic disease. 2006; 29:591. [PubMed: 16802107]
- Fensom AH, Grant AR, Steinberg SJ, Ward CP, Lake BD, Logan EC, Hulman G. An adult with a non-neuronopathic form of Niemann-Pick C disease. Journal of inherited metabolic disease. 1999; 22:84–86. [PubMed: 10070623]
- Frohlich E, Harzer K, Heller T, Ruhl U. [Ultrasound echogenic splenic tumors: nodular manifestation of type C Niemann-Pick disease]. Ultraschall in der Medizin. 1990; 11:119–122. [PubMed: 2200110]
- Cross JL, Iben J, Simpson C, Thurm A, Swedo S, Tierney E, Bailey-Wilson J, Biesecker LG, Porter FD, Wassif CA. Determination of the Allelic Frequency in Smith-Lemli-Opitz Syndrome by Analysis of Massively Parallel Sequencing Data Sets. Clinical genetics. 2014
- 20. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). Seattle, WA:
- 21. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491:56–65. [PubMed: 23128226]
- Biesecker LG, Mullikin JC, Facio FM, Turner C, Cherukuri PF, Blakesley RW, Bouffard GG, Chines PS, Cruz P, Hansen NF, et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome research. 2009; 19:1665–1674. [PubMed: 19602640]
- Chelala C, Khan A, Lemoine NR. SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. Bioinformatics. 2009; 25:655– 661. [PubMed: 19098027]
- Haas D, Garbade SF, Vohwinkel C, Muschol N, Trefz FK, Penzien JM, Zschocke J, Hoffmann GF, Burgard P. Effects of cholesterol and simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS). Journal of inherited metabolic disease. 2007; 30:375–387. [PubMed: 17497248]
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nature methods. 2010; 7:248–249. [PubMed: 20354512]

- Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature protocols. 2009; 4:1073–1081. [PubMed: 19561590]
- 27. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic acids research. 2011; 39:e118. [PubMed: 21727090]
- Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. Journal of computational biology : a journal of computational molecular cell biology. 2004; 11:377–394. [PubMed: 15285897]
- 29. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. The Human Gene Mutation Database: 2008 update. Genome medicine. 2009; 1:13. [PubMed: 19348700]
- 30. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature protocols. 2010; 5:725–738. [PubMed: 20360767]
- 31. Al-Daghri NM, Cagliani R, Forni D, Alokail MS, Pozzoli U, Alkharfy KM, Sabico S, Clerici M, Sironi M. Mammalian NPC1 genes may undergo positive selection and human polymorphisms associate with type 2 diabetes. BMC medicine. 2012; 10:140. [PubMed: 23153210]
- Tangemo C, Weber D, Theiss S, Mengel E, Runz H. Niemann-Pick Type C disease: characterizing lipid levels in patients with variant lysosomal cholesterol storage. Journal of lipid research. 2011; 52:813–825. [PubMed: 21245028]
- 33. Millat G, Bailo N, Molinero S, Rodriguez C, Chikh K, Vanier MT. Niemann-Pick C disease: use of denaturing high performance liquid chromatography for the detection of NPC1 and NPC2 genetic variations and impact on management of patients and families. Molecular genetics and metabolism. 2005; 86:220–232. [PubMed: 16126423]
- 34. Huang L, Pike D, Sleat DE, Nanda V, Lobel P. Potential Pitfalls and Solutions for Use of Fluorescent Fusion Proteins to Study the Lysosome. PloS one. 2014; 9
- 35. Park WD, O'Brien JF, Lundquist PA, Kraft DL, Vockley CW, Karnes PS, Patterson MC, Snow K. Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1. Human mutation. 2003; 22:313–325. [PubMed: 12955717]
- 36. Meyre D, Delplanque J, Chevre JC, Lecoeur C, Lobbens S, Gallina S, Durand E, Vatin V, Degraeve F, Proenca C, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet. 2009; 41:157–159. [PubMed: 19151714]
- Xu S, Benoff B, Liou HL, Lobel P, Stock AM. Structural basis of sterol binding by NPC2, a lysosomal protein deficient in Niemann-Pick type C2 disease. J Biol Chem. 2007; 282:23525– 23531. [PubMed: 17573352]
- Landau M, Mayrose I, Rosenberg Y, Glaser F, Martz E, Pupko T, Ben-Tal N. ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. Nucleic acids research. 2005; 33:W299–W302. [PubMed: 15980475]
- Glaser F, Rosenberg Y, Kessel A, Pupko T, Ben-Tal N. The ConSurf-HSSP database: The mapping of evolutionary conservation among homologs onto PDB structures. Proteins. 2005; 58:610–617. [PubMed: 15614759]
- 40. Kwon HJ, Abi-Mosleh L, Wang ML, Deisenhofer J, Goldstein JL, Brown MS, Infante RE. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell. 2009; 137:1213–1224. [PubMed: 19563754]




Figure 1.

Mapping of the coding variants onto the known structure of NPC2. Probably damaging mutations are labeled with red circles. The human NPC2 structural model (from positions 20 to 149) was created using Modeller based on the bovine NPC2 structure (PDB:2HKA)³⁷. Human NPC2 ribbon is colored according to evolutionary conservation using ConSurf server^{38; 39}. Cholesterol sulfate (from PDB:2HKA)³⁷ is shown in sticks. Beta strands are labeled (A to G).


A

ATCCCAG TACAS


TOTACTOSEAT

Author Manuscript

Author Manuscript



TTAG AG AT 6 AG



V S F S V L G G F I K C S T W L A D V

Figure 2.

Mapping human N-terminal domain (NTD)-NPC1 mutants. Probably and possibly damaging mutations are labeled with red circles. The human NTD-NPC1 (PDB:3GKI)⁴⁰ ribbon was colored according to evolutionary conservation using the ConSurf server^{39; 40}. Cholesterol is shown in sticks. None of the NTD-NPC1 mutants is located at cholesterol interacting residues.

Author Manuscript

Table 1

well variants that have been previously published are noted. Variants considered non-pathogenic are shaded grey. The number of alleles analyzed for each variant and the total number of times the variant was detected are noted in conjunction with the frequency of each variant in each of the four data sets and reference SNP "RS" number when available. The majority have been assigned either a Polyphen-2, SIFT, Mutation assessor, or MaxEntScan scores, as This table summarizes the 16,455 distinct variants detected in NPCI. Each variant has a corresponding cDNA nucleotide number, protein change, and the carrier rate for each variant.

cDNA	Protein	#sı	Polyphen-2/MaxEntScan/Published
c.110A>G	p.D37G		BENIGN
c.127G>A	p.E43K	rs138277307	BENIGN
c.180G>T	р.Q60Н	rs145666943	BENIGN
c.181-4A>C	intronic	rs374571310	Neutral
c.181-3A>G	intronic	rs371126954	Strong Negative Effect
c.209A>G	p.N70S	rs200291759	BENIGN
c.233G>A	p.R78Q	rs373274825	BENIGN
c.346C>T	p.R116X	rs144973225	PROBABLY DAMAGING/Published
c.347G>A	p.R116Q	rs140952850	BENIGN
c.410C>T	p.T137M	rs372947142	BENIGN/Published
c.424_425insGA	p.K142Rfs		
c.442G>C	p.V148L	rs200323346	BENIGN
c.445G>A	p.G149R	rs143205855	BENIGN
c.449A>G	p.Q150R	rs375940577	BENIGN
c.466A>G	p.M156V	rs149074243	BENIGN
c.467T>C	p.M156T	rs147615070	BENIGN
c.481C>T	p.R161W	rs141243713	PROBABLY DAMAGING
c.520G>C	p.G174R	rs370098528	PROBABLY DAMAGING
c.544G>A	p.D182N	rs201021988	BENIGN
c.547G>A	p.A183T	rs111256741	BENIGN
c.548C>T	p.A183V	rs192963719	BENIGN
c.553A>G	p.N185D	rs139485263	BENIGN
c.622G>C	p.V208L	rs372416248	BENIGN

Polyphen-2/MaxEntScan/Published	PROBABLY DAMAGING	BENIGN/Known polymorphism	BENIGN/Published	Published	BENIGN	BENIGN/Published benign	BENIGN	POSSIBLY DAMAGING	PROBABLY DAMAGING	BENIGN	BENIGN	POSSIBLY DAMAGING	POSSIBLY DAMAGING	BENIGN	BENIGN	BENIGN	POSSIBLY DAMAGING	BENIGN	POSSIBLY DAMAGING	BENIGN	POSSIBLY DAMAGING	PROBABLY DAMAGING	PROBABLY DAMAGING/Published						
#sı	rs367851289	rs1805081	rs55680026		rs201956601	rs80358251		rs373815982	rs371023983	rs368776731	rs374169117	rs370188327		rs370810779	rs377132020	rs138151007	rs150154006	rs138079168	rs141361998	rs199693280	rs373390781	rs370181667	rs376741451	rs149020783	rs200243024	rs150053420	rs373751051	rs371234970	rs139751448
Protein	p.D211Y	p.H215R	p.N222S	p.S230_V231del	p.D232G	p.P237S	p.K250T	p.P255S	p.P255R	p.P257S	p.T261M	p.D266G	p.Y269C	p.I271V	p.L281F	p.W291C	p.E301K	p.A321V	p.V327I	p.C334S	p.R337Q	p.R341P	p.V347I	p.C352F	p.S365L	p.R372Q	p.R389H	p.F403S	p.R404Q
cDNA	c.631G>T	c.644A>G	c.665A>G	c.688_693del	c.695A>G	c.709C>T	c.749A>C	c.763C>T	c.764C>G	c.769C>T	c.782C>T	c.797A>G	c.806A>G	c.811A>G	c.841C>T	c.873G>T	c.901G>A	c.962C>T	c.979G>A	c.1001G>C	c.1010G>A	c.1022G>C	c.1039G>A	c.1055G>T	c.1094C>T	c.1115G>A	c.1166G>A	c.1208T>C	c.1211G>A

Polyphen-2/MaxEntScan/Published	BENIGN	BENIGN	BENIGN	BENIGN/Known polymorphism	BENIGN	BENIGN	BENIGN	PROBABLY DAMAGING	PROBABLY DAMAGING/Published	BENIGN	BENIGN	BENIGN	PROBABLY DAMAGING	BENIGN	PROBABLY DAMAGING/Published	BENIGN/Published	PROBABLY DAMAGING/Published	POSSIBLY DAMAGING/Published	BENIGN	BENIGN		BENIGN	BENIGN	PROBABLY DAMAGING/Published	POSSIBLY DAMAGING	BENIGN	POSSIBLY DAMAGING	PROBABLY DAMAGING/Published	
rs#	rs77080672	rs143797098	rs140149624	rs61731962	rs372289265	rs141892620	rs374159264	rs201226297	rs372445155	rs370758521	rs199812609	rs191537721	rs13381670	rs201791992	rs377515417	rs138184115	rs369368181	rs201156397	rs369753548	rs147021046		rs201236716	rs76615690	rs202140203	rs368129141	rs112387560	rs140786703	rs376213990	
Protein	p.R411Q	p.P424A	p.S425L	p.P434S	p.A449V	p.I450V	p.S456F	p.P471L	p.P474L	p.S491N	p.V494M	p.D502E	p.T511M	p.V517I	p.R518W	p.A521S	p.P543L	p.A558S	p.E586K	p.N589S	p.Y594Lfs	p.N598S	p.V624I	p.Y634C	p.R646C	p.R646H	p.A659V	p.V664M	p.V674Lfs
cDNA	c.1232G>A	c.1270C>G	c.1274C>T	c.1300C>T	c.1346C>T	c.1348A>G	c.1367C>T	c.1412C>T	c.1421C>T	c.1472G>A	c.1480G>A	c.1506C>G	c.1532C>T	c.1549G>A	c.1552C>T	c.1561G>T	c.1628C>T	c.1672G>T	c.1756G>A	c.1766A>G	c.1780_1781insT	c.1793A>G	c.1870G>A	c.1901A>G	c.1936C>T	c.1937G>A	c.1976C>T	c.1990G>A	c.2020_2021del

Polyphen-2/MaxEntScan/Published	PROBABLY DAMAGING	PROBABLY DAMAGING/Published	PROBABLY DAMAGING	PROBABLY DAMAGING	BENIGN	PROBABLY DAMAGING	BENIGN	BENIGN	BENIGN	PROBABLY DAMAGING	PROBABLY DAMAGING	POSSIBLY DAMAGING	BENIGN/Known polymorphism	Neutral	POSSIBLY DAMAGING/Published	BENIGN	BENIGN	Neutral	PROBABLY DAMAGING/Published	PROBABLY DAMAGING/Published	PROBABLY DAMAGING/Published	BENIGN/Published		Neutral	Neutral	Published	PROBABLY DAMAGING/Published	PROBABLY DAMAGING/Published	PROBABLY DAMAGING/Published
#S1		rs370323921	rs375047023	rs201100763	rs146874573	rs193182840	rs145362908	rs145362908	rs373435883	rs190298665	rs374068891	rs139297968	rs1805082		rs372030650	rs374656358	rs34302553	rs374406578	rs370721218	rs143124972	rs120074132	rs34084984		rs186588103	rs186588103		rs80358254	rs150334966	rs80358257
Protein	p.S676T	p.L695V	p.R714H	p.L737V	p.V753M	p.V780M	p.V810L	p.V810L	p.M834T	p.F842L	p.F842S	p.A851T	p.I858V	intronic	p.D874V	p.S902C	p.G911S	intronic	p.R934X	p.S940L	p.R958Q	p.N961S	p.S970Ffs	intronic	intronic	p.991_fs	p.G992W	p.S1004L	n.P1007A
cDNA	c.2027G>C	c.2083C>G	c.2141G>A	c.2209C>G	c.2257G>A	c.2338G>A	c.2428G>T	c.2428G>C	c.2501T>C	* c.2524T>C	c.2525T>C	c.2551G>A	c.2572A>G	c.2605-6_2605-3del	c.2621A>T	c.2705C>G	c.2731G>A	c.2796-4C>T	c.2800C>T	c.2819C>T	c.2873G>A	c.2882A>G	c.2908_2909insTT	c.2911+4C>T	c.2929+4C>T	c.2972_2973del	c.2974G>T	c.3011C>T	c 3019C>G

$\mathbf{\nabla}$
2
Ħ
Ъ
0
2
\geq
Ē
\supseteq
S
Ω
<u>-</u>
0
—

Polyphen-2/MaxEntScan/Published	BENIGN	POSSIBLY DAMAGING/Published	PROBABLY DAMAGING	BENIGN	BENIGN/Published	POSSIBLY DAMAGING	BENIGN	PROBABLY DAMAGING/Published	BENIGN	BENIGN	PROBABLY DAMAGING/Published	Neutral	Negative	PROBABLY DAMAGING	BENIGN	PROBABLY DAMAGING	POSSIBLY DAMAGING	PROBABLY DAMAGING	PROBABLY DAMAGING/Published	POSSIBLY DAMAGING/Published	POSSIBLY DAMAGING/Published	BENIGN	PROBABLY DAMAGING/Published	Published	BENIGN	BENIGN	PROBABLY DAMAGING		Published
rs#	rs191876836	rs140211089	rs146666146	rs374719153	rs80358259	rs369960141	rs141440861	rs374526072	rs34226296	rs148571882	rs144725473	rs114073738		rs139612110	rs61731969	rs148035987		rs145297180	rs200444084	rs113371321	rs369098773	rs375309094	rs35248744		rs140827681	rs368658600	rs374150662		
Protein	p.K1010Q	p.H1016R	p.A1018T	p.S1020T	p.11061T	p.A1062T	p.G1073S	p.E1089K	p.V1115F	p.W1122R	p.V1141G	intronic	intronic	p.S1169I	P.M1179V	p.R1183H	p.V1184M	p.R1186C	p.R1186H	p.A1187V	p.E1189G	р.Н1193Y	p.S1200G	p.L1204Qfs	p.F1207L	p.I1223V	p.L1230S	0	p.L1248Vfs
cDNA	c.3028A>C	c.3047A>G	c.3052G>A	c.3059G>C	c.3182T>C	c.3184G>A	c.3217G>A	c.3265G>A	c.3343G>T	c.3364T>C	c.3422T>G	c.3477+4A>G	c.3498+4A>G	c.3506G>T	c.3535A>G	c.3548G>A	c.3550G>A	c.3556C>T	c.3557G>A	c.3560C>T	c.3566A>G	c.3577C>T	c.3598A>G	c.3611_3614del	c.3619T>C	c.3667A>G	c.3689T>C	c.3741_3745A	c.3742_3745del

Polyphen-2/MaxEntScan/Published	Neutral	PROBABLY DAMAGING	BENIGN/Known polymorphism	BENIGN	POSSIBLY DAMAGING	PROBABLY DAMAGING	BENIGN	BENIGN
rs#		rs376164368	rs1805084	rs373435628	rs140527006	rs200264267	rs374032318	rs151305963
Protein	intronic	p.R1266X	p.R1266Q	p.Y1267D	p.E1271Q	p.R1272C	p.E1273G	p.R1274Q
cDNA	c.3755-5_3755-4insTC	c.3796C>T	c.3797G>A	c.3799T>G	c.3811G>C	c.3814C>T	c.3818A>G	c.3821G>A

		_																			
	Rate	0.01%	0.01%	0.03%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.03%	0.01%	0.01%	0.01%	0.01%	0.04%
BENIGN	Autism	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
I	Clinseq	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
rs151305963	1000 Genome	0	0	1	0	0	1	0	0	0	0	0	2	1	0	0	0	0	0	1	3
	NHLBI	0	1	4	2	1	0	1	1	2	1	1	0	1	1	6	1	2	1	1	4
p.R1274Q	Total Variants	1	1	5	2	1	1	1	1	2	1	1	2	2	1	6	2	2	1	2	7
c.3821G>A	Total Alleles	17754	17754	17754	17754	17754	17754	17754	17754	17754	17754	17266	17754	17754	17754	17754	17734	17754	17754	17754	17754

Auth
9
-
P
Ē
S
9
Ð
t

Author Manuscript

Wassif et al.

Rate	0.01%	0.02%	0.01%	0.01%	29.67%	0.40%	0.02%	0.01%	1.03%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.06%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Autism	0	0	0	0	220	1	0	0	4	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Clinseq	0	1	0	0	646	6	0	0	15	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0	0	2	0	0
1000 Genome	1	0	0	0	535	2	0	1	14	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	0	0	0	0
NHLBI	0	3	1	1	3849	59	3	0	150	0	1	1	1	1	1	0	1	1	7	1	1	1	0	1	1	2	2	0	1	1
Total Variants	1	4	1	1	5250	11	3	1	183	1	1	1	1	1	1	1	1	1	10	1	2	1	1	1	1	2	2	2	1	1
Total Alleles	17754	17752	17754	17754	17696	17748	17226	17754	17730	17754	17754	17754	17754	17754	17754	17746	17754	17754	17754	17754	17750	17754	17754	17754	17754	17754	17754	17754	17754	17754

Genet Med. Author manuscript; available in PMC 2017 January 01.

Page 20

Rate	0.01%	0.01%	0.19%	0.01%	0.01%	1.19%	0.01%	0.03%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.29%	0.01%	0.01%	0.05%	0.01%	0.01%	0.01%	0.05%	0.01%	0.01%	0.01%	0.01%	0.01%	0.04%	0.01%	0.01%
Clinseq Autism	0 0	0 0	1 2	0 0	0 0	3 2	0 0	2 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	0 0	0 0	1 0	0 0	1 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0
1000 Genome	0	0	5	0	0	18	0	0	0	1	0	0	0	1	8	1	0	0	0	0	0	0	0	1	2	0	0	3	0	0
NHLBI	1	1	26	1	1	189	1	3	1	0	1	1	1	0	42	0	2	9	1	0	2	7	1	0	0	0	1	4	1	1
Total Variants	1	1	34	1	1	212	1	5	1	1	1	1	1	1	51	1	2	6	1	1	2	8	1	1	2	1	1	L	1	1
Total Alleles	17754	17754	17754	17754	17754	17752	17754	17752	17754	17754	17754	17754	17754	17754	17754	17754	17754	17754	17754	17704	17754	17732	17266	17754	17754	17752	17754	17754	17754	17754

Rate	1.85%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.05%	0.01%	0.01%	0.01%	0.01%	0.01%	45.09%	0.01%	0.01%	0.01%	0.39%	0.01%	0.01%	0.01%	0.01%	0.39%	0.01%	0.02%	0.01%	0.01%	0.01%	0.06%	0.02%
Autism	0	1	0	0	0	0	0	0	0	0	0	0	0	283	0	0	0	3	0	0	0	0	1	0	0	0	1	0	1	0
Clinseq	0	0	0	0	1	0	0	0	1	0	0	0	0	864	0	0	0	0	0	0	0	0	1	0	0	0	1	0	2	0
1000 Genome	0	0	0	0	0	0	1	3	0	0	1	0	0	1100	0	0	0	3	0	0	0	0	11	0	0	1	0	0	0	-
NHLBI	319	0	1	2	0	2	0	5	0	1	0	1	2	5758	1	1	1	63	1	1	1	1	56	1	3	0	0	1	8	2
Total Variants	319	1	1	2	1	2	1	8	1	1	1	1	2	8005	1	1	1	69	1	1	1	1	69	1	3	1	2	1	11	ę
Total Alleles	17266	17754	17754	17754	17754	17754	17754	17754	17752	17754	17754	17754	17754	17752	17266	17754	17754	17754	17754	17754	17754	17754	17754	17266	17754	17754	17724	17754	17750	17754

Author Manuscript Author Manuscript																															
ť	Rate	0.01%	0.01%	0.01%	0.01%	0.03%	0.01%	0.13%	0.01%	0.24%	0.01%	0.01%	0.16%	0.02%	0.01%	0.34%	0.05%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.35%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.02%
	Autism	0	0	0	0	0	0	0	0	2	1	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Autho	Clinseq	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0
Author Manuscript	1000 Genome	1	0	0	0	0	0	4	0	7	0	0	0	4	0	5	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0
ipt	NHLBI	0	1	2	1	5	1	18	1	34	1	1	28	0	2	54	7	0	2	1	0	1	1	61	1	1	1	1	0	1	4
AL	Total Variants	1	1	2	1	5	1	23	1	43	2	1	28	4	2	61	8	1	2	2	1	1	1	63	1	1	1	1	1	1	4
Author Manu	Total Alleles	17754	17754	17754	17754	17754	17754	17750	17754	17754	17754	17754	17754	17754	17754	17694	17754	17676	17754	17754	17754	17754	17754	17754	17264	17754	17754	17754	17748	17266	17266

Author Manuscript

Rate	0.01%	9.71%	0.01%	0.01%	0.01%	0.01%	0.03%
	0	41	0	0	0	0	1
Clinseq	0	101	0	0	0	0	0
1000 Genome	0	307	0	0	1	0	0
NHLBI	1	1275	1	1	0	1	4
Total Alleles Total Variants NHLBI 1000 Genome Clinseq Autism	1	1724	1	1	1	1	5
Total Alleles	17754	17754	17754	17754	17754	17754	17754

The asterisk indicates the one novel variant detected in the NIH patient.

Author Manuscript

Author Manuscript

Table2

"RS" number when available. The majority have been assigned either a Polyphen-2, SIFT, Mutation assessor, or MaxEntScan score, as well variants that have been previously published are noted. Variants considered non-pathogenic are shaded grey. The number of alleles analyzed for each variant and the total number of times the variant was detected is noted in conjunction with the frequency of each variant in each of the four data sets and the carrier rate This table summarizes the 271 distinct variants detected in NPC2. Each variant has a corresponding cDNA number; protein change and reference SNP for each variant.

cDNA	Protein	rs#	Polyphen-2/MaxEntScan/Published	Total Alleles	Total Variants	NHLBI	1000 Genome	Clinseq	Autism	Rate
c.38T>C	p.L13P	rs147602717	PROBABLY DAMAGING	17360	5	4	0	1	0	0.03%
c.49G>A	p.A17T	rs145302203	BENIGN	17748	1	1	0	0	0	0.01%
c.56C>A	p.A19D	rs369392502	PROBABLY DAMAGING	17748	1	1	0	0	0	0.01%
c.58G>T	p.E20X	rs80358260	Published	17750	1	1	0	0	0	0.01%
c.88G>A	p.V30M	rs151220873	POSSIBLY DAMAGING/Published	17252	34	25	1	4	4	0.20%
c.115G>A	p.V39M	rs80358261	PROBABLY DAMAGING/Published	17754	1	1	0	0	0	0.01%
c.212A>G	p.K71R	rs142075589	POSSIBLY DAMAGING	17754	3	2	1	0	0	0.02%
c.224A>T	p.H75L	rs369221608	PROBABLY DAMAGING	17754	1	1	0	0	0	0.01%
c.271G>A	p.D91N	rs148607507	POSSIBLY DAMAGING	17754	10	8	0	2	0	0.06%
c.278G>T	p.C93F	rs143960270	PROBABLY DAMAGING/Published	17754	1	1	0	0	0	0.01%
c.292A>C	H86N.q	rs142858704	BENIGN	17754	12	11	1	0	0	0.07%
c.340C>G	p.P114A	rs371363324	PROBABLY DAMAGING	17754	1	1	0	0	0	0.01%
c.441+1G>A	intronic	rs140130028	Strong Negative/Published	17752	96	83	0	9	L	0.54%
c.442-4A>C	intronic	rs114950106	Neutral	17754	104	104	0	0	0	0.59%